(AOF) – Inventiva has announced the selection of three scientific abstracts for poster presentation at the International Liver Congress 2022 organized by the Association for the Study of the Liver (EASL) from June 22 to 26, 2022 in London, United Kingdom . These three poster presentations demonstrate the beneficial effects of his experimental treatment lanifibranor on markers of cardiometabolic health in patients with NASH (non-alcoholic steatohepatitis) with non-cirrhotic fibrosis, independent of observed weight gain.
They also demonstrate the reduction in Fast score in association with the beneficial effects of lanifibranor on liver histology and biologically relevant biomarkers, in patients with NASH and F2/F3 fibrosis.
Finally, they demonstrate the identification of biomarkers of the histological response in patients with non-cirrhotic NASH treated with lanifibranor.
AOF – LEARN MORE
Oncology supports laboratory performance
Oncology generated $163 billion in revenue in 2021 (out of an industry total of $613 billion), up 11.9%, according to GlobalData. Its average annual growth has reached 15.4% over the past twenty years. This segment, which is increasingly competitive, is dominated by a few heavyweights such as MSD (Merck & Co. Inc), Roche, BMS
.
L
‘
immuno-oncology, the specialty that has been driving this market for ten years, supports research. GlobalData estimates that this segment could reach 180 billion in 2026. The major players are looking to strengthen themselves in this niche. Pfizer recently acquired Canadian biotech Trillium Therapeutics for $2.3 billion. Following this operation, the American group got hold of two promising molecules in the treatment of blood cancer.